抗肿瘤靶向药物风险共担谈判模式的应用研究  

Application of Risk-sharing Negotiation Model of Targeted Medicine in Oncology

作　　者：朱虹[1] 马正 刘兰茹[1] 韩月[1] 赵丹[1] 兰恭赞[3] 

机构地区：[1]哈尔滨医科大学人文社会科学学院,黑龙江哈尔滨150086 [2]北京大学人口研究所 [3]哈尔滨医科大学药学院

出　　处：《中国卫生事业管理》2017年第9期672-674,720,共4页Chinese Health Service Management

基　　金：哈尔滨医科大学创新科学研究资助项目:"医疗-医保-医药"三医联动改革视角下靶向药物"风险共担谈判"模式的研究(2016RWZX20);哈尔滨医科大学伍连德青年基金项目:病人安全影响因素的研究与实践(WLD-QN1413);四川省哲学社会科学重点研究基地--四川医事卫生法治研究中心项目:上市后药品风险管理中风险沟通模式的研究(YF15-Q07);四川省哲学社会科学重点研究基地--四川医事卫生法治研究中心项目:基本医疗保险参保人员异地就医即时结算政策研究(YF16-Y03)

摘　　要：建立药品谈判机制是现阶段药品价格改革的重要措施之一。抗肿瘤靶向药物已被国家及多省市列入重点谈判的范围并取得初步成效。积极开展靶向药物谈判工作,将其纳入医疗保险支付范围,有利于提高靶向药物的可及性,减轻肿瘤患者的用药负担。通过研究意大利、英国等发达国家靶向药物"风险共担谈判"的类型、方式及应用,为我国开展抗肿瘤靶向药物"风险共担谈判"提出建议。The establishment of drug negotiation mechanism is one of the important measures of drug price reform currently. The negotiation on targeted medicine in oncology have achieved initial results which have been enrolled in key negotia- tion scope in the national and local areas. The negotiation practice on targeted drug was advanced that was included in the scope of medical insurance payments, the accessibility of targeted drugs was improved, and the burden of cancer patients was reduced. Through the study on the type, manner and application of risk -sharing negotiation model of targeted medicine in oneology in Italy and UK, to put forward suggestions for improving it in China.

关 键 词：风险共担 风险分担协议 靶向药物 药品谈判 抗肿瘤药物 

分 类 号：R95[医药卫生—药学]